<SEC-DOCUMENT>0001213900-25-022284-index.html : 20250310
<SEC-HEADER>0001213900-25-022284.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310170003
ACCESSION NUMBER:		0001213900-25-022284
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250310
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Polyrizon Ltd.
		CENTRAL INDEX KEY:			0001893645
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42375
		FILM NUMBER:		25724612

	BUSINESS ADDRESS:	
		STREET 1:		12/6 BOROCHOV ST.
		CITY:			RAANANA
		STATE:			IL
		ZIP:			4343306
		BUSINESS PHONE:		972-54-7979668

	MAIL ADDRESS:	
		STREET 1:		12/6 BOROCHOV ST.
		CITY:			RAANANA
		STATE:			IL
		ZIP:			4343306
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0233751-6k_polyrizon.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
Document 1 - file: ea0233751-6k_polyrizon.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea023375102ex99-1_poly.htm
<DESCRIPTION>PRESS RELEASE TITLED: "POLYRIZON INITIATES PRECLINICAL STUDIES FOR INTRANASAL NALOXONE TARGETING OPIOID OVERDOSE BASED ON ITS INNOVATIVE T&T PLATFORM"
<TEXT>
Document 2 - file: ea023375102ex99-1_poly.htm

</DOCUMENT>
</SEC-DOCUMENT>